4 June 2026

Kromek Group plc 

("Kromek", the "Company" or the "Group") 

Grant of Long-Term Incentives

Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces the grant of performance-based share awards under its Long-Term Incentive Plan (the "LTIP") to Executive Directors of the Company.

The Company has granted a total of 15,566,498 share awards under its LTIP in the form of options over ordinary shares of 1p each in the Company ("Ordinary Shares") that vest subject to the achievement of certain performance criteria (the "LTIP Awards") assessed over the three financial years ending 30 April 2028. The LTIP Awards have a nominal value exercise price of 1p per Ordinary Share. The LTIP Awards have been granted to Directors of the Company as follows:

The LTIP Awards will vest subject to the Company meeting a minimum relative total shareholder return ("RTSR") equal to the FTSE AIM All-Share Index Average Total Shareholder Return ("TSR") over the performance period. 25% of the LTIP Awards will vest on meeting this minimum threshold performance criteria, with vesting thereafter on a straight-line basis up to meeting a maximum performance target of a RTSR that is 30% greater than the FTSE AIM All-Share Index Average TSR.

Once vested, the LTIP Awards may be exercised at any time until the seventh anniversary of the vest date. The vest date is the last day of the performance period if, and to the extent that, the performance criteria has been met and subsequently ratified by the Board.

Accordingly, as at 3 June 2026, the Company had options and LTIPs outstanding over a total of 76,635,732 Ordinary Shares, representing 11.7% of the Company's issued share capital, and PDMRs/Directors had the following interest in the Company's issued share capital:

Enquiries 

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them